SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

18 Jan 2023 Evaluate
Lupin has informed that it enclosed a Press Release as regards launch of launch of combination drug Sacubitril and Valsartan under two brand names, Valentas and Arnipin for patients with Heart Failure conditions. 

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2469.30 70.60 (2.94%)
03-Jul-2026 13:39 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1907.00
Dr. Reddys Labs. 1377.40
Cipla 1464.35
Zydus Lifesciences 1128.15
Lupin 2469.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: